Literature DB >> 12084660

Expression of tumor necrosis factor-alpha and interferon-gamma mRNA in blood cells correlates with depression scores during an acute attack in patients with multiple sclerosis.

K G Kahl1, N Kruse, H Faller, H Weiss, P Rieckmann.   

Abstract

Depression is a common problem in multiple sclerosis (MS) and affects about 50% of MS patients. Since a dysregulation of cytokine levels has been implicated in the pathogenesis of MS and alterations in cytokine serum levels have been found in depressive illness, we examined the relationship between depressive symptoms, cytokine mRNA expression levels of Th1-type and Th2-type cytokines and neurological disability among early diagnosed MS patients in a prospective study. Sixteen patients with clinically or laboratory supported MS were assessed using the Beck Depression Inventory (BDI) and the Kurtzke Expanded Disability Status Scale (EDSS). Cytokine mRNA in whole blood was serially determined by a new quantitative polymerase chain reaction (PCR) method. BDI sum scores (2,9 fold) and the expression levels of tumor necrosis factor-alpha (TNF-alpha; 4 fold), interferon-gamma (IFN-gamma; 4,6 fold) and interleukin-10 (IL-10; 6,1 fold) mRNA were increased in MS patients during an acute attack compared to age and sex matched healthy controls. We detected a significant positive correlation between TNF-alpha (r=0.55) and interferon-gamma (r=0.54) mRNA expression and the BDI sum scores during an acute attack in MS patients. At follow-up after 3-6 months, only TNF-alpha mRNA expression was correlated with BDI sum scores (r=0.62 resp. r=0.31). No correlation of the BDI sum scores with Th2-type cytokine mRNA expression for interleukin-4 (IL-4) and interleukin-10 (IL-10) or with the extent of neurological disability was observed. The possible contribution of Th1-type cytokines to the development of depression in MS is discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12084660     DOI: 10.1016/s0306-4530(01)00068-3

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  22 in total

1.  The immune state of bulbectomized mice.

Authors:  E G Novoselova; N V Bobkova; O A Sinotova; V B Ogai; O V Glushkova; N I Medvinskaya; A N Samokhin
Journal:  Dokl Biol Sci       Date:  2003 Nov-Dec

Review 2.  New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors.

Authors:  Michael Maes; Zdenĕk Fišar; Miguel Medina; Giovanni Scapagnini; Gabriel Nowak; Michael Berk
Journal:  Inflammopharmacology       Date:  2012-01-24       Impact factor: 4.473

3.  Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment.

Authors:  Ida S Haussleiter; Martin Brüne; Georg Juckel
Journal:  Ther Adv Neurol Disord       Date:  2009-01       Impact factor: 6.570

4.  Effects of the anti-multiple sclerosis immunomodulator laquinimod on anxiety and depression in rodent behavioral models.

Authors:  Irit Gil-Ad; Ben H Amit; Liat Hayardeni; Igor Tarasenko; Michal Taler; Ravit Uzan Gueta; Abraham Weizman
Journal:  J Mol Neurosci       Date:  2014-07-27       Impact factor: 3.444

Review 5.  [Coexistent depressive and anxiety disorders in epilepsy and multiple sclerosis: a challenge to neuropsychiatric practice].

Authors:  Hans-Peter Kapfhammer
Journal:  Neuropsychiatr       Date:  2014-05-20

Review 6.  Inflammatory cytokine-associated depression.

Authors:  Francis E Lotrich
Journal:  Brain Res       Date:  2014-07-05       Impact factor: 3.252

7.  Immune-Inflammatory and Oxidative and Nitrosative Stress Biomarkers of Depression Symptoms in Subjects with Multiple Sclerosis: Increased Peripheral Inflammation but Less Acute Neuroinflammation.

Authors:  Ana Paula Kallaur; Josiane Lopes; Sayonara Rangel Oliveira; Andrea Name Colado Simão; Edna Maria Vissoci Reiche; Elaine Regina Delicato de Almeida; Helena Kaminami Morimoto; Wildea Lice Carvalho Jennings de Pereira; Daniele Frizon Alfieri; Sueli Donizete Borelli; Domacio Ramon Kaimen-Maciel; Michael Maes
Journal:  Mol Neurobiol       Date:  2015-09-24       Impact factor: 5.590

Review 8.  Update on depression in neurologic illness: stroke, epilepsy, and multiple sclerosis.

Authors:  Richard M Sobel; Susan Lotkowski; Steven Mandel
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

9.  Depression and Age at First Neurology Appointment Associated with Receipt of Behavioral Medicine Services Within 1 Year in a Multiple Sclerosis Population.

Authors:  Benjamin Greenberg; Youran Fan; Lucille Carriere; Amy Sullivan
Journal:  Int J MS Care       Date:  2017 Jul-Aug

Review 10.  Depression and immunity: inflammation and depressive symptoms in multiple sclerosis.

Authors:  Stefan M Gold; Michael R Irwin
Journal:  Immunol Allergy Clin North Am       Date:  2009-05       Impact factor: 3.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.